Featured Research

from universities, journals, and other organizations

New Imaging Technology Shown To Detect Pancreatic Inflammation In Type 1 Diabetes

Date:
August 19, 2005
Source:
Joslin Diabetes Center
Summary:
A key obstacle to early detection of type 1 diabetes - as well as to rapid assessment of the effectiveness of therapeutic intervention - has been the lack of direct, non-invasive technologies to visualize inflammation in the pancreas, an early manifestation of disease. Instead, clinicians have had to await overt symptoms before diagnosing an individual, by which time destruction of the insulin-producing beta cells of the pancreas has already progressed significantly.

MRI visualization of diabetes progression. Left: normal mouse, right: mouse 3 days away from becoming diabetic.
Credit: Image courtesy of Joslin Diabetes Center

BOSTON - A key obstacle to early detection of type 1 diabetes - as wellas to rapid assessment of the effectiveness of therapeutic intervention- has been the lack of direct, non-invasive technologies to visualizeinflammation in the pancreas, an early manifestation of disease.Instead, clinicians have had to await overt symptoms before diagnosingan individual, by which time destruction of the insulin-producing betacells of the pancreas has already progressed significantly.

Recent proof-of-principle experiments by Joslin Diabetes Center andMassachusetts General Hospital (MGH) researchers, however, offer hopethat physicians may one day be able to identify individuals withpreclinical type 1 diabetes, and to assess the effectiveness oftherapies much earlier than is now possible. Findings of the study willbe published in the September issue of the Journal of ClinicalInvestigation.

Type 1 diabetes is an autoimmune disease in which the body'simmune system mistakenly attacks its own insulin-producing beta cellsand eventually kills them. Early in this process, white blood cellscalled T lymphocytes infiltrate the islets of the pancreas (aninflammatory condition known as insulitis), causing the blood vesselsto become leaky. Over time, this infiltration of lymphocytes destroysthe beta cells, leading to high blood glucose and full-blown diabetes.Today, the only accurate method for detecting the progression orregression of insulitis is a biopsy of the pancreas, which is almostnever performed because it is an invasive and potentially riskyprocedure.

"The most exciting aspect of this study is that itdemonstrates that we can, at least in mice, use a non-invasive imagingmethod to predict at a very early time whether a drug will stop theprogression of diabetes or not. In fact, the drug we used in theseproof-of-principle experiments is analogous to one currently beingtried in humans with diabetes, and so far showing great promise," saidDiane Mathis, Ph.D., who led the study together with ChristopheBenoist, M.D., Ph.D., also from Joslin, and Ralph Weissleder, M.D.,Ph.D., of MGH.

Drs. Mathis and Benoist head Joslin's Section on Immunologyand Immunogenetics, hold William T. Young Chairs in Diabetes Researchat Joslin, and are Professors of Medicine at Harvard Medical School.Other investigators in the study included Stuart Turvey, M.D., Ph.D.,formerly of Joslin, who is now at the University of British Columbiaand British Columbia Children's Hospital, both in Vancouver, Canada;Maria Denis, Ph.D., a former Joslin research fellow who now works atthe BSRC Alexander Fleming Institute of Immunology in Greece, and EricSwart and Umar Mahmood, M.D., Ph.D., from MGH.

In this study, the Joslin and MGH researchers used a newimaging technique to reveal the otherwise undetectable inflammation ofpancreatic islets in recently diagnosed diabetic mice. As T lymphocytesinvade the pancreas, blood vessels swell, become more permeable, andleak fluid -- as well as small molecules carried in the fluid -- intosurrounding tissues. In previous experiments, the researchersdemonstrated that this leakage can be detected with the help ofmagnetic nanoparticles (MNP) and magnetic resonance imaging (MRI).After being injected intravenously, these MNPs, which are minuteparticles of iron oxide, travel through the blood vessels of the bodyincluding the pancreas. If pancreatic vessels have become leaky frominflammation, the magnetic particles spill into nearby tissues, wherethey are "eaten" by scavenger cells called macrophages. Thus, the MNPsbecome concentrated at the inflamed site and can be spotted byhigh-resolution MRI.

In their recent study, the researchers applied the MRI-MNPtechnique to determine whether they could predict which mice woulddevelop autoimmune diabetes and monitor the effectiveness of immunetherapy aimed at reversing diabetes. The goal of this study was togather data on mouse models that could guide the safe application ofthe technique in human patients with, or at risk of, type 1 diabetes.

Results of this study suggest that the MRI-MNP imagingtechnology may be helpful in identifying people at immediate risk ofdeveloping autoimmune diabetes, but most of all for early prediction ofresponse to therapy, which might be very useful for reducing the timeand cost of clinical trials. "Because the results in mice looked sogood, and because our MGH colleagues have already successfully usedessentially the same drug on many patients with prostate cancer," saidDr. Benoist, "we have been able to move relatively quickly intoclinical trials." Dr. Turvey added: "We hope to know soon whether wecan use this drug and imaging technique to monitor pancreasinflammation in humans."

Now Recruiting for Clinical Trial
Joslin investigators are currently recruiting subjects for theImaging in Diabetes clinical trial. Subjects must be individuals overthe age of 17 who have been diagnosed with type 1 diabetes within thelast six months or who are at increased risk for developing type 1diabetes, based on family history and antibody testing. At present, thetrial is enrolling only at-risk individuals who have already been riskstratified. Qualified individuals interested in more information aboutthis trial should contact Jason Gaglia at Joslin Diabetes Center at617-732-2481 or jason.gaglia@joslin.harvard.edu.

###

About Joslin Diabetes Center
Joslin Diabetes Center, dedicated to conquering diabetes in all of itsforms, is the global leader in diabetes research, care and education.Founded in 1898, Joslin is an independent nonprofit institutionaffiliated with Harvard Medical School. Joslin research is a team ofmore than 300 people at the forefront of discovery aimed at preventingand curing diabetes. Joslin Clinic, affiliated with Beth IsraelDeaconess Medical Center in Boston, the nationwide network of JoslinAffiliated Programs, and the hundreds of Joslin educational programsoffered each year for clinicians, researchers and patients, enableJoslin to develop, implement and share innovations that immeasurablyimprove the lives of people with diabetes. As a nonprofit, Joslinbenefits from the generosity of donors in advancing its mission. Formore information on Joslin, call 1-800-JOSLIN-1 or visit www.joslin.org.


Story Source:

The above story is based on materials provided by Joslin Diabetes Center. Note: Materials may be edited for content and length.


Cite This Page:

Joslin Diabetes Center. "New Imaging Technology Shown To Detect Pancreatic Inflammation In Type 1 Diabetes." ScienceDaily. ScienceDaily, 19 August 2005. <www.sciencedaily.com/releases/2005/08/050819131319.htm>.
Joslin Diabetes Center. (2005, August 19). New Imaging Technology Shown To Detect Pancreatic Inflammation In Type 1 Diabetes. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2005/08/050819131319.htm
Joslin Diabetes Center. "New Imaging Technology Shown To Detect Pancreatic Inflammation In Type 1 Diabetes." ScienceDaily. www.sciencedaily.com/releases/2005/08/050819131319.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins